Dubé Gregory P, Vranckx Pascal, Greenburg A Gerson
Cardiovascular Research, Biopure Corporation, Cambridge, Massachusetts 02141, USA.
EuroIntervention. 2008 May;4(1):161-5. doi: 10.4244/eijv4i1a26.
Clinical and preclinical studies have revealed a diverse array of indications in which the effectiveness of HBOC-201 has been demonstrated or appears likely. Included among these are indications involving cardiac and peripheral ischaemia in which this oxygen therapeutic may prove to be an important tool in the armamentarium of the cardiologist and surgeon. Preclinical studies and clinical trials are under way to further delineate and optimise the role of HBOC-201 as an oxygen therapeutic in cardiovascular medicine.
临床研究和临床前研究已经揭示了多种适应症,在这些适应症中,HBOC-201的有效性已得到证实或似乎有可能得到证实。其中包括涉及心脏和外周缺血的适应症,在这些适应症中,这种氧疗剂可能被证明是心脏病专家和外科医生武器库中的一种重要工具。目前正在进行临床前研究和临床试验,以进一步阐明并优化HBOC-201作为心血管医学中氧疗剂的作用。